Top

Reviews in Endocrine and Metabolic Disorders

Published in:

01-12-2018

Immunoendocrinology: When (neuro)endocrinology and immunology meet

Authors: Christian A. Koch, Alessandro Antonelli

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 4/2018

Excerpt

It is with great pleasure to introduce Professor Antonelli as the Guest Editor for this special issue of Reviews in Endocrine & Metabolic Disorders. Prof. Antonelli is board certified in Internal Medicine, Endocrinology, and Oncology, and the Director of the Immuno-Endocrine Section of Internal Medicine, Head of the Laboratory of Primary Human Cells and Associate Professor in the Department of Clinical and Experimental Medicine at the University of Pisa, Italy. For this guest issue, Prof. Antonelli assembled a panel of international expert contributors to discuss current aspects of immunoendocrinology. …

Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2018. https://doi.org/10.1210/er.2018-00006.

Piranavan P, Li Y, Brown E, Kemp EH, Trivedi N. ImmuneCheckpoint inhibitor-induced Hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. J Clin Endocrinol Metab. 2018. https://doi.org/10.1210/jc.2018-01151.

Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471–80.CrossRefPubMedPubMedCentral

Moseley KF, Naidoo J, Bingham CO, Carducci MA, Forde PM, Gibney GT, et al. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: A seminal case series. J Immunother Cancer. 2018;6(1):104. https://doi.org/10.1186/s40425-018-0417-8.CrossRefPubMedPubMedCentral

Casey RT, Giger O, Seetho I, Marker A, Pitfield D, Boyle LH, et al. Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab. Semin Oncol. 2018;45:151–5.CrossRefPubMedPubMedCentral

Higham CE, Olsson-Brown A, Carroll P, Cooksley T, Larkin J, Lorigan P, et al. Society for endocrinology endocrine emergency guidance: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect. 2018;7(7):G1–7.CrossRefPubMedPubMedCentral

Paepegaey AC, Lheure C, Ratour C, Lethielleux G, Clerc J, Bertherat J, et al. Polyendocrinopathy resulting from Pembrolizumab in a patient with a malignant melanoma. J Endocr Soc. 2017;1(6):646–9.CrossRefPubMedPubMedCentral

Ferrari SM, Fallahi P, Galetta F, Citi E, Benvenga S, Antonelli A. Thyroid disorders induced by checkpoint inhibitors. Rev Endocr Metab Disord. 2018. https://doi.org/10.1007/s11154-018-9463-2.

Kalden JR, Evans MM, Irvine WJ. The effect of hypophysectomy on the immune response. Immunology. 1970;18(5):671–9.PubMedPubMedCentral

10.

Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature. 1997;390(6658):350–1.CrossRefPubMed

11.

Manger K, Wildt L, Kalden JR, Manger B. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: The PREGO-study. Autoimmun Rev. 2006;5(4):269–72.CrossRefPubMed

12.

Breedveld FC, Kalden JR, Smolen JS. Advances in targeted therapies 2017. Clin Immunol. 2018;186:1–2.CrossRefPubMed

13.

Koch CA, Mazzaferri EL, Larry JA, Fanning TS. Bullous pemphigoid after treatment with furosemide. Cutis. 1996;58(5):340–4.PubMed

14.

Koch CA, Robyn JA, Pacak K. How do levels of (endogenous) glucocorticoids, interleukin-10 and interleukin-12 relate to multiple sclerosis relapse before, during and after pregnancy? Clin Endocrinol. 1999;50(6):818–9.CrossRef

15.

Sternberg EM, Wilder RL, Gold PW, Chrousos GP. A defect in the central component of the immune system--hypothalamic-pituitary-adrenal axis feedback loop is associated with susceptibility to experimental arthritis and other inflammatory diseases. Ann N Y Acad Sci. 1990;594:289–92.CrossRefPubMed

16.

Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332(20):1351–62.CrossRefPubMed

17.

Elenkov IJ, Chrousos GP, Wilder RL. Neuroendocrine regulation of IL-12 and TNF-alpha/IL-10 balance. Clinical implications. Ann N Y Acad Sci. 2000;917:94–105.CrossRefPubMed

18.

Ott R, Bussenius-Kammerer M, Reck T, Koch CA, Kissler H, Hohenberger W, et al. Impact of changing immunosuppressive monotherapy from Cyclosporin a to Tacrolimus in long-term, stable liver transplant recipients. Transpl Int. 2004;17(1):39–43.CrossRefPubMed

19.

Lewis RE. Julius M. Cruse, Mentor and mensch. Exp Mol Pathol. 2012;93(3):288–90.CrossRefPubMed

20.

Cruse JM, Lewis RE. Immunologic research: Publishing knowledge of the future today!: the first three decades. Immunol Res. 2012;52(1–2):1.CrossRefPubMed

21.

Ejaeidi AA, Craft BS, Puneky LV, Lewis RE, Cruse JM. Hormone receptor-independent CXCL10 production is associated with the regulation of cellular factors linked to breast cancer progression and metastasis. Exp Mol Pathol. 2015;99(1):163–72.CrossRefPubMed

22.

Melcescu E, Hogan RB 2nd, Brown K, Boyd SA, Abell TL, Koch CA. The various faces of autoimmune endocrinopathies: Non-tumoral hypergastrinemia in a patient with lymphocytic colitis and chronic autoimmune gastritis. Exp Mol Pathol. 2012;93(3):434–40.CrossRefPubMedPubMedCentral

23.

Elliott SM, Erickson ML, Krall AL, Adams BA. Concentrations of pharmaceuticals and other micropollutants in groundwater downgradient from large on-site wastewater discharges. PLoS One. 2018;13(11):e0206004.CrossRefPubMedPubMedCentral

24.

Camiré A, Espinasse J, Chabot B, Lajeunesse A. Development of electrospun lignin nanofibers for the adsorption of pharmaceutical contaminants in wastewater. Environ Sci Pollut Res Int. 2018. https://doi.org/10.1007/s11356-018-3333-z.

25.

Kibuye FA, Gall HE, Elkin KR, Ayers B, Veith TL, Miller M, et al. Fate of pharmaceuticals in a spray-irrigation system: from wastewater to groundwater. Sci Total Environ. 2018;654:197–208.CrossRefPubMed

26.

Li J, Zhao H, Xia W, Zhou Y, Xu S, Cai Z. Nine phthalate metabolites in human urine for the comparison of health risk between population groups with different water consumptions. Sci Total Environ. 2019;649:1532–154.CrossRefPubMed

27.

Leusch FDL, Neale PA, Arnal C, Aneck-Hahn NH, Balaguer P, Bruchet A, et al. Analysis of endocrine activity in drinking water, surface water and treated wastewater from six countries. Water Res. 2018;139:10–5.CrossRefPubMed

28.

Guarneri F, Benvenga S. Environmental factors and genetic background that interact to cause autoimmune thyroid disease. Curr Opin Endocrinol Diabetes Obes. 2007;14(5):398–409.CrossRefPubMed

29.

Benvenga S, Guarneri F. Molecular mimicry and autoimmune thyroid disease. Rev Endocr Metab Disord. 2016;17(4):485–98.CrossRefPubMed

30.

Melcescu E, Kemp EH, Majithia V, Vijayakumar V, Uwaifo GI, Koch CA. Graves' disease, hypoparathyroidism, systemic lupus erythematosus, alopecia, and angioedema: autoimmune polyglandular syndrome variant or coincidence? Int J Immunopathol Pharmacol. 2013;26(1):217–22.CrossRefPubMed

31.

Koch CA. How can environmental factors contribute to the incidence of Thyroid Cancer? Horm Metab Res. 2017;49(3):229–31.CrossRefPubMed

32.

Koch CA. Editorial: a journey from brain to muscle across the thyroid continent. Rev Endocr Metab Disord. 2016;17(4):465–9.CrossRefPubMed

33.

Melcescu E, Horton WB, Pitman KT, Vijayakumar V, Koch CA. Euthyroid Graves' orbitopathy and incidental papillary thyroid microcarcinoma. Hormones (Athens). 2013;12(2):298–304.CrossRef

34.

Newman BD, Maher JF, Subauste JS, Uwaifo GI, Bigler SA, Koch CA. Clustering of sebaceous gland carcinoma, papillary thyroid carcinoma and breast cancer in a woman as a new cancer susceptibility disorder: A case report. J Med Case Rep. 2009;3:6905. https://doi.org/10.4076/1752-1947-3-6905.CrossRefPubMedPubMedCentral

35.

Antonelli A, Benvenga S. Editorial: the Association of Other Autoimmune Diseases in patients with Thyroid autoimmunity. Front Endocrinol (Lausanne). 2018;9:540.CrossRef

36.

Benvenga S, Antonelli A, Vita R. Thyroid nodules and thyroid autoimmunity in the context of environmental pollution. Rev Endocr Metab Disord. 2015;16(4):319–40.CrossRefPubMed

37.

De Luca F, Shoenfeld Y. The microbiome in autoimmune diseases. Clin Exp Immunol. 2018. https://doi.org/10.1111/cei.13158.

38.

Vatanen T, Franzosa EA, Schwager R, Tripathi S, Arthur TD, Vehik K, et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature. 2018;562(7728):589–94.CrossRefPubMedPubMedCentral

39.

Virili C, Fallahi P, Antonelli A, Benvenga S, Centanni M. Gut microbiota and Hashimoto's thyroiditis. Rev Endocr Metab Disord. 2018. https://doi.org/10.1007/s11154-018-9467-y.

40.

Koch CA. Editorial: “The Koch’s” view on the sense of taste in endocrinology. Rev Endocr Metab Disord. 2016;17(2):143–7.CrossRefPubMed

41.

Langer-Gould A, Brara SM, Beaber BE, Koebnick C. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology. 2013;80(6):548–52.CrossRefPubMedPubMedCentral

42.

Khan U, Bloom RA, Nicell JA, Laurenson JP. Risks associated with the environmental release of pharmaceuticals on the U.S. Food and Drug Administration “flush list”. Sci Total Environ. 2017;609:1023–40.CrossRefPubMed

43.

Colafrancesco S, Agmon-Levin N, Perricone C, Shoenfeld Y. Unraveling the soul of autoimmune diseases: Pathogenesis, diagnosis and treatment adding dowels to the puzzle. Immunol Res. 2013;56(2–3):200–5.CrossRefPubMed

44.

Watad A, David P, Brown S, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants and Thyroid autoimmunity. Front Endocrinol (Lausanne). 2017;7:150. https://doi.org/10.3389/fendo.2016.00150.CrossRef

45.

Segal Y, Dahan S, Sharif K, Bragazzi NL, Watad A, Amital H. The value of Autoimmune syndrome induced by adjuvant (ASIA) - shedding light on orphan diseases in autoimmunity. Autoimmun Rev. 2018;17(5):440–8.CrossRefPubMed

46.

Freiberger SN, Leuthard DS, Duda A, Contassot E, Thallmair M, Kündig TM, et al. Intraperitoneal administration of aluminium-based adjuvants produces severe transient systemic adverse events in mice. Eur J Pharm Sci. 2018;115:362–8.CrossRefPubMed

47.

Witebsky E, Rose NR, Terplan K, Paine JR, Egan RW. Chronic thyroiditis and autoimmunization. JAMA. 1957;164:1439–47.CrossRef

48.

Hänninen A, Soilu-Hänninen M, Hampe CS, Deptula A, Geubtner K, Ilonen J, et al. Characterization of CD4+ T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with stiff-person syndrome but without type 1 diabetes. Diabetes Metab Res Rev. 2010;26(4):271–9.CrossRefPubMedPubMedCentral

49.

Bosi E, Boulware DC, Becker DJ, Buckner JH, Geyer S, Gottlieb PA, et al. Type 1 diabetes TrialNet study group. Impact of age and antibody type on progression from single to multiple autoantibodies in type 1 diabetes relatives. J Clin Endocrinol Metab. 2017;102(8):2881–6.CrossRefPubMedPubMedCentral

50.

Triolo TM, Fouts A, Pyle L, Yu L, Gottlieb PA, Steck AK, et al. Identical and nonidentical twins: risk and factors involved in development of islet autoimmunity and type 1 diabetes. Diabetes Care. 2018. https://doi.org/10.2337/dc18-0288.

51.

Ehlers M, Jordan AL, Feldkamp J, Fritzen R, Quadbeck B, Haase M, et al. Anti-Thyroperoxidase antibody levels >500 IU/ml indicate a moderately increased risk for developing hypothyroidism in Autoimmune thyroiditis. Horm Metab Res. 2016;48(10):623–9.CrossRefPubMed

52.

Spencer CA, Hollowell JG, Kazarosyan M, Braverman LE. National Health and Nutrition Examination Survey III thyroid-stimulating hormone (TSH)-thyroperoxidase antibody relationships demonstrate that TSH upper reference limits may be skewed by occult thyroid dysfunction. J Clin Endocrinol Metab. 2007;92(11):4236–40.CrossRefPubMed

53.

Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489–99.CrossRefPubMed

54.

Hershman JM, Cheng SY, Gianoukakis AG. Update in thyroidology 2010. J Clin Endocrinol Metab. 2011;96(1):9–14.CrossRefPubMed

55.

Benvenga S, Cahnmann HJ, Rader D, Kindt M, Robbins J. Thyroxine binding to the apolipoproteins of high density lipoproteins HDL2 and HDL3. Endocrinology. 1992;131(6):2805–11.CrossRefPubMed

56.

Mondello P, Mian M, Pitini V, Cuzzocrea S, Sindoni A, Galletti M, et al. Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? Curr Oncol. 2016;23(3):e165–70.CrossRefPubMedPubMedCentral

57.

Benvenga S, Bartalena L, Antonelli A, Li Calzi L, Di Pasquale G, Trimarchi F, et al. Radioimmunoassay for human thyroxine-binding prealbumin. Ann Clin Lab Sci. 1986;16(3):231–40.PubMed

58.

Antonelli A, Carmassi F, Neri S, Saracino A, Gambuzza C, Alberti B, et al. Inappropriate antidiuretic hormone secretion in a patient with systemic sarcoidosis. Recenti Prog Med. 1992;83(9):492–5.PubMed

59.

Antonelli A, Navarranne A, Palla R, Alberti B, Saracino A, Mestre C, et al. Pretibial myxedema and high-dose intravenous immunoglobulin treatment. Thyroid. 1994 Winter;4(4):399–408.CrossRefPubMed

60.

Baschieri L, Antonelli A, del Guerra P, Fialdini A, Gasperini L. Somatostatin effect in postprandial hypoglycemia. Metabolism. 1989;38(6):568–71.CrossRefPubMed

61.

Pacini F, Antonelli A, Lari R, Gasperini L, Baschieri L, Pinchera A. Unsuspected parathyroid cysts diagnosed by measurement of thyroglobulin and parathyroid hormone concentrations in fluid aspirates. Ann Intern Med. 1985;102(6):793–4.CrossRefPubMed

62.

Chung KJ, Nati M, Chavakis T, Chatzigeorgiou A. Innate immune cells in the adipose tissue. Rev Endocr Metab Disord. 2018. https://doi.org/10.1007/s11154-018-9451-6.

63.

Kourtzelis I, Li X, Mitroulis I, Grosser D, Kajikawa T, Wang B, et al. DEL-1 promotes macrophage efferocytosis and clearance of inflammation. Nat Immunol. 2018. https://doi.org/10.1038/s41590-018-0249-1.

64.

Vita R, Ieni A, Tuccari G, Benvenga S. The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma. Rev Endocr Metab Disord. 2018. https://doi.org/10.1007/s11154-018-9474-z.

65.

Aleisa A, Lim Y, Gordon S, Her MJ, Zancanaro P, Abudu M, et al. Response to ustekinumab in three pediatric patients with alopecia areata. Pediatr Dermatol. 2018. https://doi.org/10.1111/pde.13699.

66.

Cranwell WC, Lai VW, Photiou L, Meah N, Wall D, Rathnayake D, et al. Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol. 2018. https://doi.org/10.1111/ajd.12941.

67.

Mikhaylov D, Pavel A, Yao C, Kimmel G, Nia J, Hashim P, et al. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res. 2018. https://doi.org/10.1007/s00403-018-1876-y.

68.

Jang YH, Hong NS, Moon SY, Eun DH, Lee WK, Chi SG, et al. Long-term prognosis of alopecia Totalis and alopecia Universalis: a longitudinal study with more than 10 years of follow-up: Better than reported. Dermatology. 2017;233(2–3):250–6.CrossRefPubMed

69.

Baldini E, Odorisio T, Tuccilli C, Persechino S, Sorrenti S, Catania A, et al. Thyroid diseases and skin autoimmunity. Rev Endocr Metab Disord. 2018. https://doi.org/10.1007/s11154-018-9450-7.

70.

Gubbi S, Hannah-Shmouni F, Stratakis CA, Koch CA. Primary Hypophysitis and Other Autoimmune disorders of the Sellar and Suprasellar regions. Rev Endocr Metab Disord. 2018. https://doi.org/10.1007/s11154-018-9480-1.

71.

Fallahi P, Ferrari SM, Elia G, Ragusa F, Paparo SR, Caruso C, et al. Myoinositol in autoimmune thyroiditis and hypothyroidism. Rev Endocr Metab Disord. 2018. https://doi.org/10.1007/s11154-018-9477-9.

72.

Ferrari SM, Elia G, Ragusa F, Paparo SR, Caruso C, Benvenga S, et al. The protective effect of myoinositol on human thyrocytes. Rev Endocr Metab Disord. 2018. https://doi.org/10.1007/s11154-018-9476-x.

73.

Bhanat E, Koch CA, Parmar R, Garla V, Vijayakumar V. Somatostatin receptor expression in non-classical locations - clinical relevance? Rev Endocr Metab Disord. 2018;19(2):123–32.CrossRefPubMed

74.

Sakane T, Suzuki N. The role of somatostatin in the pathophysiology of rheumatoid arthritis. Clin Exp Rheumatol. 1998;16(6):745–9.PubMed

75.

Kamphuis LS, Kwekkeboom DJ, Missotten TO, Baarsma GS, Dalm VA, Dik WA, et al. Somatostatin receptor scintigraphy patterns in patients with sarcoidosis. Clin Nucl Med. 2015;40(12):925–9.CrossRefPubMed

76.

Koch CA, Krabbe S, Hehmke B. Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties ? Rev Endocr Metab Disord. 2018. https://doi.org/10.1007/s11154-018-9478-8.

77.

Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. The National Lipid Association's muscle safety expert panel. An assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58–71.CrossRefPubMed

78.

McGrath ER, Doughty CT, Amato AA. Autoimmune Myopathies: Updates on evaluation and treatment. Neurotherapeutics. 2018;15(4):976–994. https://doi.org/10.1007/s13311-018-00676-2.

79.

Caughey GE, Gabb GM, Ronson S, Ward M, Beukelman T, Hill CL, et al. Association of Statin Exposure with Histologically Confirmed Idiopathic Inflammatory Myositis in an Australian population. JAMA Intern Med. 2018;178(9):1224–9.CrossRefPubMedPubMedCentral

80.

Colaci M, Malatino L, Antonelli A, Fallahi P, Giuggiolo D, Ferri C. Endocrine disorders associated with hepatitis C virus chronic infection. Rev Endocr Metab Disord. 2018. https://doi.org/10.1007/s11154-018-9475-y.

81.

Fabiani S, Fallahi P, Ferrari SM, Miccoli M, Antonelli A. Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature. Rev Endocr Metab Disord. 2018. https://doi.org/10.1007/s11154-017-9440-1.

Title: Immunoendocrinology: When (neuro)endocrinology and immunology meet
Authors: Christian A. Koch
Alessandro Antonelli
Publication date: 01-12-2018
Publisher: Springer US
Published in: Reviews in Endocrine and Metabolic Disorders / Issue 4/2018
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-018-9479-7

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2018

The protective effect of myo-inositol on human thyrocytes

Thyroid disorders induced by checkpoint inhibitors

The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma

Endocrine disorders associated with hepatitis C virus chronic infection

Thyroid diseases and skin autoimmunity

Gut microbiota and Hashimoto’s thyroiditis

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage